Abstract:Simple Summary Breast cancer (BC) is a serious threat to women's health and metastasis is the major cause of BC-associated mortality. Failure to detect and remove occult micrometastases limits the control of tumor recurrences. More precise non-invasive strategy needs to be developed for the detection of the tumor metastasis in lymph nodes and distant organs. Here, we suppose that the metabolomic method can be used to achieve non-invasive and real-time monitoring of BC metastatic status. We firstly described the metastatic status of BC mouse models with different tumor-bearing times. Secondly, metabonomics analysis and metastasis-related changes in the tumor microenvironment (TME) were performed in tumor-bearing mice with different metastatic states. The results showed that TME evolution can establish a link between metabolomics characteristics and tumor metastatic status. Finally, the changes of differential metabolite levels were also preliminarily confirmed in clinical BC samples and found that metabolite lysoPC (16:0) can be used for clinical N-stage diagnosis, and the possible causes of its changes was analyzed through bioinformatics technology. Breast cancer (BC) is a serious threat to women's health and metastasis is the major cause of BC-associated mortality. Various techniques are currently used to preoperatively describe the metastatic status of tumors, based on which a comprehensive treatment protocol was determined. However, accurately staging a tumor before surgery remains a challenge, which may lead to the miss of optimal treatment options. More severely, the failure to detect and remove occult micrometastases often causes tumor recurrences. There is an urgent need to develop a more precise and non-invasive strategy for the detection of the tumor metastasis in lymph nodes and distant organs. Based on the facts that tumor metastasis is closely related to the primary tumor microenvironment (TME) evolutions and that metabolomics profiling of the circulatory system can precisely reflect subtle changes within TME, we suppose whether metabolomic technology can be used to achieve non-invasive and real-time monitoring of BC metastatic status. In this study, the metastasis status of BC mouse models with different tumor-bearing times was firstly depicted to mimic clinical anatomic TNM staging system. Metabolomic profiling together with metastasis-related changes in TME among tumor-bearing mice with different metastatic status was conducted. A range of differential metabolites reflecting tumor metastatic states were screened and in vivo experiments proved that two main metastasis-driving factors in TME, TGF-beta and hypoxia, were closely related to the regular changes of these metabolites. The differential metabolites level changes were also preliminarily confirmed in a limited number of clinical BC samples. Metabolite lysoPC (16:0) was found to be useful for clinical N stage diagnosis and the possible cause of its changes was analyzed by bioinformatics techniques.

Time-course changes in potential biomarkers detected using a metabonomic approach in Walker 256 tumor-bearing rats.

Largescale Multicenter Study of a Serum Metabolite Biomarker Panel for the Diagnosis of Breast Cancer

Integrative Analysis of Plasma Metabolomics and Proteomics Reveals the Metabolic Landscape of Breast Cancer

Urinary metabonomic study on colorectal cancer.

Dynamic Changes of Urine Proteome in a Walker 256 Tumor‐bearing Rat Model

Early biomarker discovery in urine of Walker 256 subcutaneous rat model

Biotransformation-based Metabolomics Profiling Method for Determining and Quantitating Cancer-Related Metabolites.

RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer.

Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery.

Early candidate biomarkers in urine of Walker-256 lung metastasis rat model.

Preliminary Study of the Metabonomics for Bio - Marks in Mice Breast Cancer

Dynamic Urinary Proteomic Analysis in a Walker 256 Intracerebral Tumor Model

Cancer Biomarker Discovery In Urine Of Walker 256 Tumor-Bearing Models

Targeted Metabolic Analysis of Nucleotides and Identification of Biomarkers Associated with Cancer in Cultured Cell Models

Exploring Metabolomics Biomarkers for Evaluating the Effectiveness of Concurrent Radiochemotherapy for Cervical Cancers.

Non-Invasive and Real-Time Monitoring of the Breast Cancer Metastasis Degree via Metabolomics

Metabonomics Study on the Effects of the Ginsenoside Rg3 in a Beta-Cyclodextrin-based Formulation on Tumor-Bearing Rats by a Fully Automatic Hydrophilic Interaction/reversed-Phase Column-Switching HPLC-ESI-MS Approach.

Evaluation of Untargeted Metabolomic Strategy for the Discovery of Biomarker of Breast Cancer

Urine Proteome Changes in Rats Subcutaneously Inoculated with Approximately Ten Tumor Cells

Metabolomic Comparison of Patients With Colorectal Cancer at Different Anticancer Treatment Stages

LC-based targeted metabolomics analysis of nucleotides and identification of biomarkers associated with chemotherapeutic drugs in cultured cell models.